Alexey Semyanov

Prof. Alexey Semyanov

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
CECarole Escartin
Carole Escartin
EGElena Galea
Elena Galea
ALAndrás Lakatos
András Lakatos
JOJames P. O’cAllaghan
James P. O’cAllaghan
GPGabor C. Petzold
Gabor C. Petzold
Alexei VerkhratskyAlexei Verkhratsky
Alexei Verkhratsky

1 May 2004 in Trends in Neurosciences
Verified
Journal Article
Closed access
ASAlexey Semyanov
Alexey Semyanov
MWMatthew C. Walker
Matthew C. Walker
DKDimitri Michael Kullmann
Dimitri Michael Kullmann
RSR.Angus Silver
R.Angus Silver

28 April 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZHZhao Huang
Zhao Huang
NXNa Xie
Na Xie
PIPeter Illes
Peter Illes
FVFrancesco Di Virgilio
Francesco Di Virgilio
HUHenning Ulrich
Henning Ulrich
YTYong Tang
Yong Tang
Purines and their derivatives, most notably adenosine and ATP, are the key molecules controlling intracellular energy homoeostasis and nucleotide synthesis. Besides, these purines support, as chemical messengers, purinergic transmission throughout tissues and species. Purines act as endogenous ligands that bind to and activate plasmalemmal purinoceptors, which mediate extracellular communication referred to as “purinergic signalling”. Purinergic signalling is cross-linked with other transmitter networks to coordinate numerous aspects of cell behaviour such as proliferation, differentiation, migration, apoptosis and other physiological processes critical for the proper function of organisms. Pathological deregulation of purinergic signalling contributes to various diseases including neurodegeneration, rheumatic immune diseases, inflammation, and cancer. Particularly, gout is one of the most prevalent purine-related disease caused by purine metabolism disorder and consequent hyperuricemia. Compelling evidence indicates that purinoceptors are potential therapeutic targets, with specific purinergic agonists and antagonists demonstrating prominent therapeutic potential. Furthermore, dietary and herbal interventions help to restore and balance purine metabolism, thus addressing the importance of a healthy lifestyle in the prevention and relief of human disorders. Profound understanding of molecular mechanisms of purinergic signalling provides new and exciting insights into the treatment of human diseases.

7 April 2003 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
ASAlexey Semyanov
Alexey Semyanov
MWMatthew C. Walker
Matthew C. Walker
DKDimitri Michael Kullmann
Dimitri Michael Kullmann

1 September 2020 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PDF file
ASAlexey Semyanov
Alexey Semyanov
Christian HennebergerChristian Henneberger
Christian Henneberger
AAAmit Agarwal
Amit Agarwal

1 October 2021 in Trends in Neurosciences
Verified
Journal Article
Closed access
ASAlexey Semyanov
Alexey Semyanov
Alexei VerkhratskyAlexei Verkhratsky
Alexei Verkhratsky